Mon, 09.01.2023 - 00:58
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
Amsterdam, the Netherlands
argenx SE today announced its strategic priorities for 2023 and provided preliminary financial results for the full year 2022, including global net product sales of VYVGART® (efgartigimod alfa-fcab).
Past Press Releases
Get photos, fact sheets, illustrations and more.
Join the team
Dare to do more with a thriving career at Argenx.
Get the latest news and info via our social media channels.